0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessWhile demonstrating a favorable safety profile, danicopan resulted in incomplete and inadequately sustained inhibition of AP, probably due to limitations in its PK/PD profile in C3G, leading to lack of efficacy. Complete and sustained AP inhibition is required for a clinical response in patients with C3G.
Carla Nester, Gerald B. Appel, Andrew S. Bomback, Koenraad Peter Bouman, H. Terence Cook, Erica Daina, Bradley P. Dixon, Kara Rice, Nader Najafian, James Hoi Po Hui, Steven D. Podos, Craig B. Langman, Liz Lightstone, Samir V. Parikh, Matthew C. Pickering, C. John Sperati, Howard Trachtman, James Tumlin, Aiko P. J. de Vries, Jack F.M. Wetzels, Giuseppe Remuzzi (2022). Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. , 53(10), DOI: https://doi.org/10.1159/000527167.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2022
Authors
21
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1159/000527167
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
.webp){kind=avatar}
